CQDM and SPM Therapeutics fund a study carried out by Professor Boilard at the CHU de Québec-Université Laval to develop a treatment for systemic lupus erythematosus

News & Events

Montreal (Quebec), June 16th, 2022 – CQDM is proud to announce the funding of a project in collaboration with the centre hospitalier universitaire (CHU) de Québec-Université Laval, SPM Therapeutics, and the Fondation du CHU de Québec. The funding, totalling $103,158, was made possible by a grant of $51,847 from the Ministère de l’Économie et de l’Innovation (MEI) for this project. … Read More

Make a difference! Job Opportunity: controller

News & Events

ABOUT CQDM  Since its creation, CQDM has raised nearly $190 million to fund the development of approximately 130 drugs addressing major health concerns, including cancer, and neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium with the socially responsible mission of funding the development of innovative tools and technologies that accelerate the development of safe and effective drugs that benefit all … Read More

CQDM funds an innovative project with Altus Formulation and Tetra Bio-Pharma to develop first-in-class treatments for ocular inflammation

News & Events

MONTREAL, April 28 2022 – CQDM is proud to announce the launch of a $5,254,895 project exploring new class of drugs to treat eye pain and blindness. The ministère de l’Économie et de l’Innovation (MEI) will provide $1,268,682 to the project as part of CQDM’s SynergiQC program which, combined with support from public institutions (Mitacs and NSERC) and Quebec companies, … Read More

CQDM and NanoGene Therapeutics Fund the Development of a Treatment for Psoriasis

News & Events

Montreal, Quebec, March 10th, 2022 – CQDM is proud to announce the funding of a project in collaboration with the Centre de recherche de l’Hôpital du Sacré-Cœur de Montréal (CIUSSS NIM), NanoGene Therapeutics, the Hôpital du Sacré-Cœur de Montréal Foundation and the Chaire de recherche en orthopédie de l’Université de Montréal. The funding, totalling $333,334, was made possible by a … Read More

SAVE THE DATE / Bio+ech Connec+ event taking place on Wednesday March 16th

News & Events

Montréal – Québec – March 1st, 2022 – CQDM Is proud to partner with BIOTECanada to present the next Bio+ech Connec+ event taking place on Wednesday, March 16th and featuring Merck.  Bio+ech Connec+, is a unique forum for early-stage Canadian biotech companies to connect directly with the business development and investment leaders of multinational pharma/biotech companies. This virtual forum will include a plenary … Read More

Le CQDM s’associe à Neurasic Therapeutics, CSVS et la Fondation Louise et Alan Edwards pour financer le développement d’un analgésique non opiacé

News & Events

Montréal (Québec), le 12 janvier 2022 – Le CQDM est fier d’annoncer l’octroi d’une subvention, en collaboration avec l’Université McGill, Neurasic Therapeutics, l’initiative Cerveau en santé, vie en santé (CSVS) de l’Université McGill et la Fondation Louise et Alan Edwards. Ce projet de recherche collaborative dirigé par le professeur Philippe Séguéla, un neuroscientifique de renommée mondiale et pionnier de l’identification … Read More